156 related articles for article (PubMed ID: 19822902)
1. The impact of prophylactic fresh-frozen plasma and cryoprecipitate on the incidence of central nervous system thrombosis and hemorrhage in children with acute lymphoblastic leukemia receiving asparaginase.
Abbott LS; Deevska M; Fernandez CV; Dix D; Price VE; Wang H; Parker L; Yhap M; Fitzgerald C; Barnard DR; Berman JN
Blood; 2009 Dec; 114(25):5146-51. PubMed ID: 19822902
[TBL] [Abstract][Full Text] [Related]
2. Solving coagulation conundrums: comparing prophylaxis strategies in adult patients receiving PEG-asparaginase.
Chen Y; Buhlinger K; Perissinotti AJ; Schepers AJ; Benitez L; Auten J; Chen SL; Bixby DL; Burke PW; Pettit KM; Marini BL
Leuk Lymphoma; 2022 Nov; 63(11):2663-2670. PubMed ID: 35699966
[TBL] [Abstract][Full Text] [Related]
3. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study.
Mitchell L; Andrew M; Hanna K; Abshire T; Halton J; Wu J; Anderson R; Cherrick I; Desai S; Mahoney D; McCusker P; Chait P; Abdolell M; de Veber G; Mikulis D
Thromb Haemost; 2003 Aug; 90(2):235-44. PubMed ID: 12888870
[TBL] [Abstract][Full Text] [Related]
4. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study.
Mitchell LG; Andrew M; Hanna K; Abshire T; Halton J; Anderson R; Cherrick I; Desai S; Mahoney D; McCuster P; Wu J; Dahl G; Chait P; de Veber G; Lee KJ; Mikulis D; Ginsberg J; Way C;
Cancer; 2003 Jan; 97(2):508-16. PubMed ID: 12518376
[TBL] [Abstract][Full Text] [Related]
5. Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL study.
Hunault-Berger M; Chevallier P; Delain M; Bulabois CE; Bologna S; Bernard M; Lafon I; Cornillon J; Maakaroun A; Tizon A; Padrazzi B; Ifrah N; Gruel Y;
Haematologica; 2008 Oct; 93(10):1488-94. PubMed ID: 18728028
[TBL] [Abstract][Full Text] [Related]
6. Low plasma levels of hemostatic proteins during the induction phase in children with acute lymphoblastic leukemia: A retrospective study by the JACLS. Japan Association of Childhood Leukemia Study.
Hongo T; Okada S; Ohzeki T; Ohta H; Nishimura S; Hamamoto K; Yagi K; Misu H; Eguchi N; Suzuki N; Horibe K; Ueda K
Pediatr Int; 2002 Jun; 44(3):293-9. PubMed ID: 11982900
[TBL] [Abstract][Full Text] [Related]
7. Fresh frozen plasma has no beneficial effect on the hemostatic system in children receiving L-asparaginase.
Halton JM; Mitchell LG; Vegh P; Eves M; Andrew ME
Am J Hematol; 1994 Nov; 47(3):157-61. PubMed ID: 7524313
[TBL] [Abstract][Full Text] [Related]
8. Different profile of thrombin generation in children with acute lymphoblastic leukaemia treated with native or pegylated asparaginase: A cohort study.
Rozen L; Noubouossie D; Dedeken L; Huybrechts S; Lê PQ; Ferster A; Demulder A
Pediatr Blood Cancer; 2017 Feb; 64(2):294-301. PubMed ID: 27605400
[TBL] [Abstract][Full Text] [Related]
9. Cerebral venous thrombosis in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma during induction chemotherapy with l-asparaginase: The GRAALL experience.
Couturier MA; Huguet F; Chevallier P; Suarez F; Thomas X; Escoffre-Barbe M; Cacheux V; Pignon JM; Bonmati C; Sanhes L; Bories P; Daguindau E; Dorvaux V; Reman O; Frayfer J; Orvain C; Lhéritier V; Ifrah N; Dombret H; Hunault-Berger M; Tanguy-Schmidt A
Am J Hematol; 2015 Nov; 90(11):986-91. PubMed ID: 26214580
[TBL] [Abstract][Full Text] [Related]
10. Cryoprecipitate-induced mesenteric venous thrombosis during L-asparaginase therapy for acute lymphoblastic leukaemia.
Musa MO; Al-Fair F; Al-Mohareb F; Al-Saeed H; Aljurf M
Leuk Lymphoma; 2001 Jan; 40(3-4):429-31. PubMed ID: 11426567
[TBL] [Abstract][Full Text] [Related]
11. A syndrome of thrombosis and hemorrhage complicating L-asparaginase therapy for childhood acute lymphoblastic leukemia.
Priest JR; Ramsay NK; Steinherz PG; Tubergen DG; Cairo MS; Sitarz AL; Bishop AJ; White L; Trigg ME; Levitt CJ; Cich JA; Coccia PF
J Pediatr; 1982 Jun; 100(6):984-9. PubMed ID: 6953221
[TBL] [Abstract][Full Text] [Related]
12. Correction of hemostatic imbalances induced by L-asparaginase therapy in children with acute lymphoblastic leukemia.
Zaunschirm A; Muntean W
Pediatr Hematol Oncol; 1986; 3(1):19-25. PubMed ID: 3153215
[TBL] [Abstract][Full Text] [Related]
13. Antithrombin deficiency after prolonged asparaginase treatment in children with acute lymphoblastic leukemia.
Ranta S; Heyman MM; Jahnukainen K; Taskinen M; Saarinen-Pihkala UM; Frisk T; Söderhäll S; Petrini P; Mäkipernaa AM
Blood Coagul Fibrinolysis; 2013 Oct; 24(7):749-56. PubMed ID: 24056293
[TBL] [Abstract][Full Text] [Related]
14. Incidence and risk factors for Central Nervous System thrombosis in paediatric acute lymphoblastic leukaemia during intensive asparaginase treatment: a single-centre cohort study.
Duarte X; Esteves S; Neto AM; Pereira F
Br J Haematol; 2016 Jul; 174(2):280-91. PubMed ID: 27018199
[TBL] [Abstract][Full Text] [Related]
15. Thromboembolism prophylaxis in adult patients with acute lymphoblastic leukemia treated in the GRAALL-2005 study.
Orvain C; Balsat M; Tavernier E; Marolleau JP; Pabst T; Chevallier P; de Gunzburg N; Cacheux V; Huguet F; Chantepie S; Caillot D; Chalandon Y; Frayfer J; Bonmati C; Lheritier V; Ifrah N; Dombret H; Boissel N; Hunault-Berger M
Blood; 2020 Jul; 136(3):328-338. PubMed ID: 32321172
[TBL] [Abstract][Full Text] [Related]
16. Sequelae of thrombotic or hemorrhagic complications following L-asparaginase therapy for childhood lymphoblastic leukemia.
Ott N; Ramsay NK; Priest JR; Lipton M; Pui CH; Steinherz P; Nesbit ME
Am J Pediatr Hematol Oncol; 1988; 10(3):191-5. PubMed ID: 3177809
[TBL] [Abstract][Full Text] [Related]
17. L-Asparaginase lowers plasma antithrombin and mannan-binding-lectin levels: Impact on thrombotic and infectious events in children with acute lymphoblastic leukemia.
Merlen C; Bonnefoy A; Wagner E; Dedeken L; Leclerc JM; Laverdière C; Rivard GE
Pediatr Blood Cancer; 2015 Aug; 62(8):1381-7. PubMed ID: 25820776
[TBL] [Abstract][Full Text] [Related]
18. Venous thromboembolism following L-asparaginase treatment for lymphoid malignancies in Korea.
Lee JH; Lee J; Yhim HY; Oh D; Bang SM
J Thromb Haemost; 2017 Apr; 15(4):655-661. PubMed ID: 28150907
[TBL] [Abstract][Full Text] [Related]
19. Acquired Hypofibrinogenemia Before Asparaginase Exposure During Induction Therapy for Pediatric Acute Lymphoblastic Leukemia: A Report of 2 Cases and Review of the Literature.
Raikar SS; Felker J; Patel KN; Lew G; Sidonio RF
J Pediatr Hematol Oncol; 2018 Oct; 40(7):e470-e472. PubMed ID: 29401102
[TBL] [Abstract][Full Text] [Related]
20. Bleeding and thrombosis in children with acute lymphoblastic leukaemia, treated according to the ALL-BFM-90 protocol.
Sutor AH; Mall V; Thomas KB
Klin Padiatr; 1999; 211(4):201-4. PubMed ID: 10472550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]